Weekly newsletter

Coronavirus: DK Enquires about Price of Chinese Vaccine

MTI-Hungary Today 2021.01.27.

The opposition Democratic Coalition has turned to the government to enquire about the price of China’s Covid-19 vaccine, citing reports that the jab “could be extremely expensive” compared with other vaccines.

China’s Sinopharm vaccine, which the European Medicines Agency (EMA) has yet to approve or even review, will reportedly cost 30 US dollars per dose, but could even reach 145 dollars when purchased in smaller quantities, DK group spokesman Zoltán Varga told an online press conference on Wednesday.

Hungarian Vaccine Politics: Heated Dispute Over Sinopharm
Hungarian Vaccine Politics: Heated Dispute Over Sinopharm

The Chinese Sinopharm vaccine has stirred up a clash of ideas in Hungary between the government’s representative’s and the opposition. The opposition criticize what they view as the rushed procurement of the vaccine, while the Hungarian government defends its reliability, as well as their decision regarding its procurement. Opposition Parties Accuse Fidesz Opposition Democratic Coalition […]Continue reading

Meanwhile, the AstraZeneca jab, which the EMA is expected to authorise at the end of the month, will cost about 2.50 dollars per dose, Varga said.

When it comes to saving lives, vaccine costs are what matter the least, he said, adding however that the 35-fold price difference between the jabs in question “is an eerie reminder of the case of the Chinese ventilators still collecting dust in our warehouses”.

Everything You Need to Know About The Chinese Sinopharm Vaccine
Everything You Need to Know About The Chinese Sinopharm Vaccine

Both Prime Minister Viktor Orbán and the Head of the Prime Minister’s Office Gergely Gulyás have stated that the Chinese Sinopharm vaccine will be shipped to Hungary as soon as Hungarian authorities allow its use. Here is what you need to know about this vaccine.  The Hungarian government has reserved 19.7 million doses of the […]Continue reading

Varga emphasised that the biggest problem was that the Sinopharm shot had not been licenced by the EMA. “An effective and safe vaccine is worth every penny, but this is not true for an unknown vaccine that has not been reviewed and whose effectiveness is uncertain,” he said.

Featured photo by Zoltán Balogh/MTI